Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation
Name
Oncogenic KRAS Regulates.pdf
Size
3.54 MB
Format
Adobe PDF
Checksum (MD5)
bec4fd117a44224893f30ef99027a5c9
Author(s)
Ling, Stephanie
Dimitriadi, Maria
McMahon, Kelly M.
Worboys, Jonathan D.
Leong, Hui Sun
Norrie, Ida C.
Miller, Crispin J.
Poulogiannis, George
Jørgensen, Claus
Tape, Christopher
Date Issued
April 2016
Journal
Cell
Publisher
Elsevier
Citation
Tape, Christopher J. et al. “Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation.” Cell 165.4 (2016): 910–920.
Version
Final published version
Abstract
Oncogenic mutations regulate signaling within both tumor cells and adjacent stromal cells. Here, we show that oncogenic KRAS (KRAS[superscript G12D]) also regulates tumor cell signaling via stromal cells. By combining cell-specific proteome labeling with multivariate phosphoproteomics, we analyzed heterocellular KRAS[superscript G12D] signaling in pancreatic ductal adenocarcinoma (PDA) cells. Tumor cell KRAS[superscript G12D] engages heterotypic fibroblasts, which subsequently instigate reciprocal signaling in the tumor cells. Reciprocal signaling employs additional kinases and doubles the number of regulated signaling nodes from cell-autonomous KRAS[superscript G12D]. Consequently, reciprocal KRAS[superscript G12D] produces a tumor cell phosphoproteome and total proteome that is distinct from cell-autonomous KRAS[superscript G12D] alone. Reciprocal signaling regulates tumor cell proliferation and apoptosis and increases mitochondrial capacity via an IGF1R/AXL-AKT axis. These results demonstrate that oncogene signaling should be viewed as a heterocellular process and that our existing cell-autonomous perspective underrepresents the extent of oncogene signaling in cancer.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Terms of Use
Creative Commons Attribution 4.0 International License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.cell.2016.03.029
